Guillain-Barré syndrome and fulminant encephalomyelitis following Ad26.COV2.S vaccination: double jeopardy

Neurological Research and Practice

Elisabeth Andreadou¹  Eleni Boutati²  Eleni Bakola³  Maria Ioanna Stefanou³  Konstantinos Voumvourakis³  Georgios Tsivgoulis³  Maria Chondrogianni³  Konstantinos Melanis³  Aikaterini Foska³  Eleni Karachaliou³  Christos Moschovos³  Matilda Papathanasiou⁴ 

[1] First Department of Neurology, Aeginition Hospital, National and Kapodistrian University of Athens, Athens, Greece;Second Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, “Attikon” University Hospital, Athens, Greece;Second Department of Neurology, National and Kapodistrian University of Athens, School of Medicine, “Attikon” University Hospital, Rimini 1, Chaidari, 12462, Athens, Greece;Second Department of Radiology, National and Kapodistrian University of Athens, School of Medicine, “Attikon” University Hospital, Athens, Greece;

关键词: Guillain-Barré syndrome;    Encephalomyelitis;    Transverse myelitis;    Ad26.COV2.S;    SARS-CoV-2 vaccine;   

DOI  :  10.1186/s42466-022-00172-1

来源: Springer

【 摘 要 】

This correspondence comments on a published article presenting a case of rhombencephalitis following SARS-CoV-2-vaccination with the mRNA vaccine BNT162b2 (Pfizer/BioNTech). We also present the case of a 47-year-old man who developed Guillain-Barré-syndrome and a fulminant encephalomyelitis 28 days after immunization with Ad26.COV2.S (Janssen/Johnson & Johnson). Based on the presented cases, we underscore the importance of clinical awareness for early recognition of overlapping neuroimmunological syndromes following vaccination against SARS-CoV-2. Additionally, we propose that that role of autoantibodies against angiotensin-converting enzyme 2 (ACE2) and the cell-surface receptor neuropilin-1, which mediate neurological manifestations of SARS-CoV-2, merit further investigation in patients presenting with neurological disorders following vaccination against SARS-CoV-2.

【 授权许可】

CC BY